Ep192: Kate Haviland on Following the Science to Precision Immunology
08.01.2026 · 1 Std. 26 Min.
Shownotes
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.